MDA 2022 poster: Associations between daily deflazacort or prednisone and ages at disease progression milestones among patients with Duchenne muscular dystrophy (DMD)
This poster, presented at the 2022 MDA Conference in Nashville, Tennessee, USA, shows the results of a study comparing 2 corticosteroids in delaying disease progression milestones in patients with DMD
Read about the background and methods of a study comparing 2 corticosteroids in delaying decline in ambulatory function in patients with DMD
Review the baseline characteristics of 463 patients treated with either prednisone or deflazacort
Explore the results of the 2 cohorts, which compare progression milestones, including measures of timed rise from floor, inability to rise from floor, inability to complete 4-stair climb, and loss of ambulation
Deflazacort is a corticosteroid indicated for the treatment of DMD in patients 2 years of age and older. PTC Therapeutics is the Marketing Authorization Holder for deflazacort in the US only. Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The US Prescribing Information for deflazacort is available here. Please refer to your local country guidance for more information.
For medical information, product complaints, or to report an adverse event, please call 1-866-562-4620 or email at email@example.com. You may also report adverse events directly to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-DMD-2200045 I March 2022
Sign in or register to access exclusive content on this site